C. Daniel Myers to Join Board of Directors of Kala Pharmaceuticals

A new director has been named to Kala Pharmaceuticals' Board.

FREMONT, CA: Top management is accountable for defining rules, standards, and strategic objectives, as well as for leading and directing quality management efforts inside the firm. It should identify persons liable for a range of management system processes and keep them accountable. C. Daniel Myers has been named to the Kala Pharmaceuticals Board of Directors, a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing new medicines for eye illnesses. Myers will join the Compensation and Nominating and Corporate Governance Committees, bringing a wealth of ophthalmic pharmaceutical experience to the table.

On his new position as the Director of Boards, Mr. C. Daniel Myers states, “I am excited to support Kala in its efforts to change the treatment paradigm for ocular diseases and am particularly enthusiastic about the opportunity for EYSUVIS to meaningfully improve the care of people living with dry eye disease. I look forward to collaborating with the management team and the other members of Kala’s Board, and to offering my perspective on strategic initiatives including the expansion of Kala’s pipeline.”

“We are very pleased to welcome Dan to our Board of Directors,” adds Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals. “Dan has an extensive background in ophthalmology and his commercial and significant corporate strategy experience will be instrumental as we execute on our vision of delivering new therapies for people living with ocular disease. We look forward to his insights on our commercial products EYSUVIS® and INVELTYS®, as well as with his guidance more broadly as we pursue our goal of establishing Kala as a leader in the treatment of eye diseases.”

MediPrint Ophthalmics, Inc.'s (previously Leo Lens Pharma's) Chief Executive Officer is Mr. Myers, who has been in that role since 2020. His previous position was as co-founder and CEO of Alimera Sciences, where he is still a non-executive chairman of the Board. Mr. Myers worked for Novartis Ophthalmics (previously CIBA Vision Ophthalmics) from 1997 to 2003, where he was president, and served as vice president of sales and marketing from 1991 to 1997, before starting Alimera. From 2009 until 2012, he was on the Board of Ocular Therapeutix, Inc. Mr. Myers graduated from Georgia Institute of Technology with a B.S. in Industrial Management.

“We are sincerely thankful to Rajeev for his many contributions, which have been instrumental in enabling Kala to mature from a private, clinical-stage company into a publicly traded commercial organization,” continues Mr. Iwicki. “Rajeev has been a great partner and made significant contributions to Kala’s evolution. We wish him the best in his future endeavors.”

Kala also confirmed that Rajeev Shah, a member of the company's Board of Directors since 2015, will step down in line with Mr. Myers' appointment.